Risk of proton pump inhibitors treatment in relationship to SARS-CoV-2 disease


Authors: Peter Vaňuga 1;  Juraj Payer 2;  Milan Kriška 3;  František Sándor 4;  Andrej Dukát 2
Authors‘ workplace: Národný endokrinologický a diabetologický ústav, n. o., Ľubochňa 1;  V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava 2;  Ústav farmakológie a klinickej farmakológie LF UK v Bratislave 3;  Klinika pneumológie a ftizeológie LF UK a UNB, Nemocnica Ružinov, Bratislava 4
Published in: Forum Diab 2022; 11(1): 39-42
Category:

Overview

Medicína v dobe pandémie SARS-CoV-2 našu klinickú prax postavila pred celkom nové problémy. Jedným z nich predstavujú aj riziká pre toto infekčné ochoreníe. Okrem všeobecne známych rizík, ako je vek a komorbidity, sa ukázala byť dôležitá aj trvajúca zavedená liečba pacientov. V tomto kontexte je potrebné sa zamerať na jednu skupinu liekov vo farmakoterapii – PPI, nakoľko sa jedná o veľmi častú liečbu v klinickej praxi všade vo svete. Diskusie o tejto liečbe sa s poznatkami vyvíjajú a stále pokračujú.

Keywords:

PPI – therapy – SARS-CoV-2


Sources

1. Almano CHV, Chey WD, Spiegel MBR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115(10): 1707–1715. Dostupné z DOI: <http://dx.doi.org/10.14309/ajg.0000000000000798>
.2. Marks D. Time to halt the overprescribing of proton pump inhibitors. Clin Pharm 2016; 8(8). Dostupné z DOI: <http://dx.doi.org/doi.org/10.1211/CP.2016.20201548>.
3. Martinsen TC, Fossmark R, Waldum HL. The phylogeny and biological function of gastric juice-microbiological cosequences of removing gastric acid. Int J Mol Sci 2019; 20(23): 6031. Dostupné z DOI: <http://dx.doi.org/doi.org/10.3390/ijms.20236031>.
4. Vilcu AM, Sabatte L, Blanchon T et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. JAMA Netw Open 2019; 2(11): e1916205. <http://dx.doi.org/10.1001/jamanetworkopen.2019.16205>.
5. Xiao F, Tamg M, Zheng X ei al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020: 158(6): 1831–1833. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2020.02.055>.
6. Zhang H, Liao YS, Gong J et al. Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: a report of 164 cases. Dig Liver Dis 2020; 52(10): 1076–1079. Dostupné z DOI: <http://dx.doi.org/doi.org/10.1016/j.dld.2020.04.034>.
7. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(20)30183–5>.
8. Luxenburger H, Sturm L, Biever P et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med 2021; 289(1): 121–124. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.13121>.
9. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183(3): 310–319. Dostupné z DOI: <http://dx.doi.org/10.1503/cmaj.092129>.
10. Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Invest 2020; 40(10): 897–899. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261–020–00963-x>.
11. Chen X, Liao B, Cheng L et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020; 104/18): 7777–7785. Dostupné z DOI: <http://dx.doi.org/10.1007/s00253–020–10814–6>.
12. Lim YK, Kweon OJ, Kim HR et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis 2019; 94(1): 1: 50–54. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diagmicrobio.2018.11.014>.
13. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. Eur J Intern Med 2020; 76: 97–99. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2020.04.043>.
14. Dukát A, Kubíková E, Payer J, Šimko F. Aké sú možné úlohy črevného mikrobiómu v procese vývoja endotelovej dysfunkcie a následnej aterosklerózy? Int Med 2018; 18(9): 383–385.
15. Homolak J, Kodvanj I, Trkulja V. An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19. Clin Drug Invest 2021; 41(3): 287–289. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261–021–01007–8>.
16. Lee SW, Ha EK, Yeniova AO et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021; 70(1): 76–84. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2020.322248>.
17. Toubasi AA, AbuAzenh RB, Khraisat BR et al. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res 2021; 52(6): 656–659. Dostupné z DOI: <http://dx.doi.org/10.1016/j.arcmed.2021.03.004>.
18. Li GF, An XX, Yu Y et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. BMJ Gut 2021; 70(9): 1806–1808. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2020–323366>.
19. Yang M, He Q, Gao F et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Medicine 2021: 19(1): 316. Dostupné z DOI: <http://doi.org/10.1186/s12916–021–02189–5>.
20. Lim YK, Kweon OJ, Kim HR et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis 2019; 94(1):50–54. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diagmicrobio.2018.11.014>.
21. Xiao F, Tamg M, Zheng X et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158(6): 1831–1833. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2020.02.055>.
22. Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect 2017; 145(8): 1617–1623. Dostupné z DOI: <http://dx.doi.org/10.1017/S0950268817000528>.
23. Kow CHB, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Int Med 2021; 289(1): 125–128. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.13183>.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account